Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Arena, Beacon Ink Strategic Immunotherapy Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Arena, Beacon Ink Strategic Immunotherapy Alliance

To develop promising compounds for a variety of immune and inflammatory diseases across a range of G protein-coupled receptor targets

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Arena Pharmaceuticals, Inc. and Beacon Discovery have entered into a strategic multi-year partnership (Project Cabrillo) aimed at developing novel medicines across a range of G protein-coupled receptor (GPCR) targets.
 
Beacon will be responsible for drug discovery activities and Arena will focus on developing and commercializing promising compounds for a variety of immune and inflammatory diseases that complement their first- or best-in-class pipeline. Financial terms were not disclosed.

“Project Cabrillo expands our relationship with Beacon Discovery, allowing us to continue to unlock the value of Arena’s legacy world-class GPCR discovery engine,” said Amit D. Munshi, president and chief executive officer of Arena. “Our work will cover a broad range of novel and validated targets which we have collectively identified and look promising. We are excited to work with Beacon to discover new medicines which we hope will dramatically change the lives of patients.”

“We are thrilled to bolster our long-standing relationship with Arena and look forward to continuing our successful track record of discovering and engineering highly-optimized compounds,” said Sunny Al-Shamma, Beacon’s chief executive officer. “We are confident that our expanded partnership will result in novel best-in-disease medicines targeting the challenging treatment of autoimmune diseases.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics